NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Valuation Check As Regulatory Scrutiny Meets Aggressive Growth Plans
Hims & Hers Health (HIMS) is in the spotlight after U.S. Senator Jim Banks urged the FDA and FTC to review its GLP-1 advertising and subscription practices, just as the company ramps up growth initiatives.
See our latest analysis for Hims & Hers Health.
At a share price of US$26.19, Hims & Hers has swung sharply over the past year, with a 90 day share price return of 18.19% contrasting with a year to date decline of 21.61% and a 1 year total shareholder return down 53.51%. This suggests...